Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Socinski on the Role of Immunotherapy in PD-L1–Negative Lung Cancer

February 6th 2021

Mark A. Socinski, MD, discusses the role of immunotherapy in PD-L1–negative lung cancer.

Dr. Borghaei on Selecting Single-Agent Versus Combination Therapy in Lung Cancer

February 6th 2021

Hossein Borghaei, DO, MS, discusses selecting between single-agent versus combination therapies in lung cancer.

Systemic Treatment Options Expand in Nonmetastatic NSCLC

February 5th 2021

Although advances in diagnosis and treatment have led to improvements in overall survival for patients with NSCLC, low rates of survival outcomes are present even in those with nonmetastatic disease.

Pralsetinib Approval Expands Options for RET-Positive Thyroid Cancers

February 5th 2021

Lori J. Wirth, MD, , discusses the potential impact of pralsetinib on the thyroid cancer treatment landscape.

Surgery Stakes Claim in Lung Cancer Despite Evolution of Systemic Therapy

February 5th 2021

Surgical resection should be a standard of care for patients with stage I to IIIA lung cancer, but probing for subclinical stage III disease with endobronchial ultrasound guided biopsy or mediastinoscopy to determine whether surgery should be performed prior to or after systemic therapy.

Hanhan Highlights How Robotic Techniques Have Shifted Surgical Care in Lung Cancer

February 4th 2021

Ziad Hanhan MD, MPH, FACS, highlights the evolution of surgery in the field of lung cancer, the advantages associated with robotic techniques, and the crucial role of the surgeon in determining eligibility for these approaches.

2020 Approvals Expand Access to Care for Patients Across Tumor Types

February 4th 2021

In a year marked by collaboration and innovation, therapeutic developments in oncology care once again dominated the novel drug approvals in 2020.

Low-Dose Chest CT Reduces Lung Cancer Mortality, but Barriers Remain

February 3rd 2021

Florian Fintelmann, MD, discusses lung cancer screening with low-dose chest CT, barriers to testing, and the potential expansion of USPSTF lung cancer screening guidelines.

FDA Approves Tepotinib for METex14-Altered Metastatic NSCLC

February 3rd 2021

February 3, 2021- The FDA has granted an accelerated approval to tepotinib for adult patients with metastatic non–small cell lung cancer harboring MET exon 14 skipping alterations.

Ceralasertib/Durvalumab Combo Shows Efficacy in NSCLC Following Anti–PD-L1 Therapy

February 3rd 2021

February 3, 2021 - The combination of ceralasertib plus durvalumab improved overall response rate in patients with non‒small cell lung cancer who progressed on an anti-PD-1/PD-L1 therapy.

Dr. Ramalingam on the Efficacy of Trastuzumab Deruxtecan in HER2+ NSCLC

February 2nd 2021

Suresh S. Ramalingam, MD, FASCO, discusses the efficacy of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive non–small cell lung cancer.

Larotrectinib Elicits Early Clinical Activity in NTRK Fusion–Positive Lung Cancer

February 2nd 2021

February 2, 2021 — Larotrectinib was found to elicit high response rates, durable responses, and to extend survival benefit in patients with advanced lung cancer whose tumors harbor an NTRK gene fusion, including those with central nervous system metastases.

QoL, Efficacy Data Support Use of Frontline Lorlatinib as New Standard in ALK+ NSCLC

February 2nd 2021

February 2, 2021 - The time to treatment deterioration for symptoms such as cough, dyspnea, and pain in the chest was found to be comparable between treatment-naïve patients with ALK-positive non–small cell lung cancer who received lorlatinib versus crizotinib.

Virtual Prehabilitation Improves Activity Level, Exercise Capacity Prior to Lung Cancer Surgery

February 2nd 2021

February 2, 2021 - Virtual prehabilitation could potentially improve physical activity level and exercise capacity in patients with lung cancer before they undergo surgery for their disease.

Dr. Spigel Discusses Advances in Early-Stage Lung Cancer

February 1st 2021

David Spigel, MD, discusses advances in early-stage lung cancer treatment.

cfDNA Methylation Assay Allows for Early Lung Cancer Detection

February 1st 2021

February 1, 2021 — Targeted circulating tumor DNA methylation marker panels possess the potential for early blood-based detection of lung cancer with a high sensitivity and specificity.

Sanborn and Gaffar Share Clinical and Economic Treatment Insights in NSCLC

February 1st 2021

In our exclusive interview, Dr. Sanborn and Dr. Gaffar share insight into the clincal and economic considerations for treatment in advanced NSCLC.

Ongoing Novel Immunotherapy Trial Builds on PACIFIC Benefits in Stage III NSCLC

February 1st 2021

Dan Costin, MD, discusses his strategies for patients with early-stage lung cancer and ongoing trials that could improve outcomes even further.

Sequist Calls 2020 a Banner Year in Lung Cancer, But Leaves Much to Be Desired

February 1st 2021

Lecia V. Sequist, MD, discusses some of the biggest advancements of 2020 in lung cancer.

Repotrectinib Elicits Early Responses in ROS1+ Metastatic NSCLC

January 31st 2021

January 31, 2021 - Repotrectinib, a next-generation ROS1 and TRK TKI, has demonstrated encouraging objective responses with acceptable tolerability in patients with ROS1 fusion–positive non–small cell lung cancer.